Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Adebrelimab · Hepatocellular Carcinoma · Transformation · Bevacizumab · TACE
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Study leads
Jianbo Chen
Principal Investigator
The First Affiliated Hospital of Xiamen University
Feng Ye
Principal Investigator
The First Affiliated Hospital of Xiamen University
congren Wang
Study Director
Quanzhou First Hospital
Qinghe Cai
Study Director
Affiliated Hospital of Putian University
Jiafei Chen
Study Director
Putian First Hospital
Yongzhong Wang
Study Director
Sanming Second Hospital
Feng Lin
Study Director
Ningde Mindong Hospital